Windtree Therapeutics, Inc. WINT

WINT Company Overview

Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cardiovascular and cardiopulmonary diseases, with an emphasis on acute conditions with high unmet medical need. The company operates within the biotechnology and pharmaceutical development industry, primarily advancing proprietary drug candidates through clinical development rather than commercial sales. Windtree does not currently generate material product revenue and relies on equity financing, licensing arrangements, and collaborations to fund operations.

Windtree’s core strategic focus is on istaroxime, a novel investigational therapy being developed for cardiogenic shock and acute heart failure, conditions associated with high mortality and limited treatment options. The company evolved from its earlier identity as Discovery Laboratories, which historically focused on respiratory therapies, including synthetic surfactant technology. Over time, Windtree transitioned its strategy toward cardiovascular drug development, rebranding as Windtree Therapeutics to reflect this shift.